in the u.k., our regulatory body, the u.s. fda has to do a final check on the data, and all of that has to be scrutinized. the eyes of the world will be on this data once it becomes available to the public. it will be the most highly scrutinized clinical trial to date, and i think it needs to be in order to not damage trust any further. as i mentioned earlier, it is essential that we do not compromise any of the safety because the damage that we see in the long term will be such that it will be almost irreversible. imran: the astrazeneca-oxford university study will be published in "the lancet." do think once transparency is in place, once we see the data, do you think that will help? >> certainly. i think peer-reviewed is absolutely essential. i think one of the challenges we face with many of the vaccines is many companies may claim results before it is peer-reviewed. that is a challenge. that has led to some discord in the scientific community as well as the public. i think there will be a different perspective in terms of the

leyen said the european medicines agency is in regular contact with the u.s. fdahronize the approval. ms. von der leyen: if all proceeds with no problem, that tells us that the conditional marketing authorization for biontech and moderna could happen as early as the second half of december 2020. leigh-ann: the world health organization is recommending against using gilead's remdesivir to treat covid-19 patients. the advice comes just weeks after regulators granted approval. says there is currently no evidence that the antiviral improves survival rates. gilead says it is disappointed and the guidelines do ignore the science. tesla is leading gains in ev stocks, hitting another record high. the latest vote of confidence is coming from the u.k. it is now looking at growing its fleet of electric cars as a way to create jobs and balance the power grid. companies in the sector have been confident electric cars will dominate the future of the market. and that is your bloomberg business flash. francine? francine: leigh-ann, thank you so much. now, coming up, we speak to t

we are in daily discussions with them, what we will do, as soon as we get approval or eua by the u.s. fda we will ship the product. we are very active in the seasonal flu process as well. we will get the vaccines out to hospitals and pharmacies. , cvs,ure you read walgreens, all of the big pharmacy chains have signed up to get a vaccine, to provide administration in the pharmacies. ceoie: that was the moderna earlier. for more, we are joined by the professors of international health and director of vaccine safety at the johns hopkins school of public health. changer? game did you wake up this morning delighted by the news? from is a good indication two companies that they appear to have effective vaccines. but they are press releases. no one has seen the data, i have not seen the data as shared publicly. it is a good indication that there are still a lot of details to follow. on that front, there are many details before this is even a consideration, but we know emergency use will be requested from regulators. what is your sense of how quickly that will translate into action, in other word

u.s. government. fda will review these vaccines and therapeutics, advice,l also have the the advisory, from board to the fda for vaccine -- after review of the data transparently and available to everybody before the fda then makes its decision to either authorize the vaccine or not. on that basis, i personally feel comfortable to say that the vaccines and therapeutics that we have developed will be judged independently, and if approved, should be used by all in the population. because i believe vaccination is likely to be the cornerstone among all the other measures we have to take to help us really control this pandemic. i will now pass to michael leader, who will tell you more about the support the operation has provided to manufacturing of the vaccine and also distribution. >> mr. president, thank you for allowing me to continue service of our great nation as the coleader on this mission. let me start by emphasizing for me what is operation warp speed is about -- it is about saving lives. it is a herc

. >>> a federal court judge ordered the u.s. fdahe safety of genetically modified salmon. the ruling centers on salmon that is genetically modified to grow faster than normal salmon. in 2015 the fish became the first genetically modified animal approved for human consumption in the u.s. the salmon already has been sold in limited quantities in canada where it doesn't have to be labeled as genetically modified. the company said the salmon are not yet being sold in the u.s. >>> hundreds of law enforcement officers took to the streets across northern california. it was the annual torch run fundraiser benefiting the special olympics. we checked in with some of the 60 renters from the san jose police who ran a 5 1/2 mile course. each mile run equals money raised for the special olympics of northern california. >> holding this torch means so much. special olympics has been a huge part of my life for many years. i've been volunteering, i love doing it, meaning the athletes and being able to give them metals and hug them.>> very cool, effor

lisa: i do think it is significant in this announcement that the public meeting with the u.s. fda is being scheduled for december 17. i think this is interesting because perhaps we will get a better sense of the rollout, how quickly we could get vaccinated, how quickly we can stop wearing masks and move on with life. but i agree with you, this is baked in at this point. the question for a lot of people looking at markets after the wondernth, you have to what will give this another leg higher. how much good news is baked in? how much does reality have to catch up? jonathan: the rustle up a 20%, absolutely amazing. this vaccine has passed several trials over the last several months. looking at the equity market more broadly, it is monday morning, which means we have to catch up with sam fazeli of bloomberg intelligence. do you like what you hear, how quickly we can get to that destination this market is already pricing in? sam: good morning, jonathan. the update moderna put out is not just about the fact that they are filing, but also that they've got a full analysis of 196 covert c

assuming the fda green lights this for emergency use authorization, i have a lot of confidence in our u.s. fdathey've got the most extraordinary track record the world has ever seen in terms of vaccine safety and efficacy, so i have really zero hesitation. in fact, i'm quite eager to get any of those vaccines because they'll all give me virus neutralizing antibodies in my system and i'm recommending them for family members as well. we do have a lot of vaccine hesitancy in this country and a lot of that is due because we've got a very aggressive anti-vaccine lobby here. my hope is that as the first round of individuals starts get vaccinated and people see no untoward effects that some of that will loosen up a little bit and we won't be -- things won't be as bad as some of the surveys seem to indicate right now. >> dr. walensky, i want to take a step back because it's so important to provide good, thorough information about vaccines as dr. hotez noted. there's a lot of misinformation out there, and it's infuriating when we talk about side effects. what can people expect? >> i think there's reall

because we know pfizer and biontech have submitted to the u.s. fda for emergency use authorization.ow, at the state level, vaccines do you believe that you guys may have access to, and how will they be distributed? >> yes. so, that's a great question. so, so much is in flux. things are changinge ing day by. we get regular briefings. what we're thinking we might get up to 400,000 doses. and so, again that number is absolutely subject to change. so, all of our firm calculations are hard. but we know for the ultra cold storage, we've identified the areas where we have ultra cold storage. we've gotten 20 additional units that we can position all around the state to make sure that there won't be a part. state that won't have access to the appropriate storage container with which to dispense this valuable resource. starting in that first stage, stage 1a in health care and first responders. >> so, governor pritzker said with the numbers there could be a statewide lockdown. what's the threshold, and how close is illinois to that? >> yeah. so, again, this is supposed to be the stopgap so we

under fda regulations, any manufacturing plant that is sending its drugs into the u.s. s to be inspected by the fda. so on paper the system of regulation is identical but the reality is that when the fda inspects plants in the u.s., they show up unannounced. they stay as long as needed. but because of all the complex logistics of overseas inspections, the fda will announce that it is coming months in advance for overseas inspections. so that gives manufacturing plants the opportunity to clean up, which they do. one of the things that i expose is how they send data fabrication teams into these plants when they have advanced notice, which they routinely do, and they will make up documents. they will backdate documents. they will shred documents. they will sometimes even create new documents and steam them overnight in a sauna room to make them look old, , is one example that i uncovered. the question is not just are they required to inspect, what is the quality of those inspections? right off the bat you have a very different situation. it goes downhill from there. one of

announcing that finally we are submitting our application for emergency use authorization to the u.s. fdahris: doesn't president trump deserve credit, in fact a great deal of credit, for operation warp speed and the private partner -- private - private-public partnership which has resulted in two vaccines in less than ten months with more on the way? >> yes. i think he does. but let's understand that the pharma companies started ahead of warp speed to start developing these vaccines and developed them in a brand-new way, so yes he does, congress does too. congress provided $10 billion in the cares act in march, which give a jump-start to moderna, which had virtually no ability to do this. pfizer did. pfizer has been much more successful, robust company and now they are both almost at the finish line at one more point, chris. developing a vaccine is great. getting them in people's arms is the new challenge and i want president trump to be first in line getting one of those vaccines so that he can show millions of americans who still think we need to stop the steel that these are safe and e

approval bye got an the u.s. fda. a marcus and.uct vi because we are very active in that process. to get the vaccines how to hospitals and pharmacies. aid, all the, rite big pharmacy chains in the u.s. have signed up to get the vaccine to provide administration in the pharmacy. this will be available in hospitals, in some rural areas and community hospitals, gp's office. so, there is a lot of work going on. taking care of that stuff. whereas administering is being involved help with logistics. >> stefan, one of the key questions as we watch the case count climbing, what impact will these shots have on transmission? what effect if i have this in my arm would have on my ability if i get the virus to transmit it to others? >> yes, and this we don't know yet. you get our vaccine you will have a 94% chance to have no covid disease. that is a big deal. ceohat was the moderna speaking with guy johnson. coming up, how gaming company razr is planning demand for new consoles. we will hear from the ceo. this is bloomberg. ♪ beenay-at-home stocks have one of the biggest beneficiaries from the

with u.s. fda three, in the open, so we can, we are prepared for and initiate as phase three study in the u.s. and your best well. so this is very -- and europe as well. from china and then pushed to global locations to address largest chinese population and patients outside china. also we have another drug, anti-part -- a d.c. drug. -- avc drug. rishaad: i want to just get to the drug in our pipeline at the moment which are most excited about. what does it do? how close is it to getting onto the market? >> yes. two drugs. in china we applied the new drug [indiscernible] . meanwhile we approved ways may be a couple of months and another a be six months. so they will come to market very soon. global, weu.s. side are still going to initial doing clinical trials, so still need to wait a little more. when are you going to be profitable? uh, well as a biotech company, weep push harder into the market but we still have a lot of drugs in the pipeline. so i depends on how much you spend money on research,

agency is incines regular contact with the u.s. fda to synchronize approval.nal marketing authorization for coulda and biontech happen as early as the second half of december 2020. anna: microsoft is a vowing to challenge all government request to access customer information. it is an effort to address european concerns on the security of data sent to the u.s. the software giant says it will also compensate customers whose information is inappropriately disclosed to government agencies. global investment. time is running out for joe biden to put a stamp on an overhaul. it is cord mating overall efforts to get nearly 140 countries to agree on a joint digital tax plan by the summer. that does not leave -- live much time -- leave much time. let's have a conversation about global investment into ireland. martin shanahan is the ida trying to encourage direct foreign investment into ireland. we will come to the question around tax in a moment but when we look ahead to 2021, how is the pipeline looking as foreign investment director? martin: the global environment is

i really think the u.s. fdansider the pfizer vaccine first and the madonna vaccine, those officially developed ones and astrazeneca will take a backseat to that, thein any event, astrazeneca vaccine has been seen as something more for middle income countries and lower income countries because it's much cheaper and can be produced across a wide range of countries so we have always seen it kind of has a great solution for the rest of the world. last hour,ke to you the u.k. has come out and said that they would like to consider approval of the astrazeneca vaccine even before the e.u. considers it and it looks like the u.k. really wants to go the full steam ahead there. it could be that it's approved in the u.k. and then europe and then may be the u.s. after that. we know it vaccine will be part of the biden administration's pandemic handling plan. in the meantime, we have heard a little bit more from president trump speaking to reporters today, saying it would be a very hard thing to concede. what are we waiting fo

u.s. and the fda authorizes the first at-home test kit. >>> return to the skies. the grounded boeing 737 max expected to fly again. good morning. good to be with you. i'm anne-marie green. we begin this morning with president trump's efforts to reverse the results of the presidential election. mr. trump fired the top cyber official after the agency he has rejected the allegations of voter fraud. >> joe biden is building out his white house staff as the trump administration continues to block his move into office. from washington, what is on tap for mr. biden today? >> president-elect joe biden is going to be meeting in a virtual round table with front-line health care workers. he's pushing forward despite president trump continuing to falsely claim he's won the election. >> two weeks after election day, supporters of president trump cheered on the president in pennsylvania. >> i want to help support the president and what he's doing and make sure all the legal votes get counted. >> president trump lost pennsylvania to joe biden by more than 80,000 votes. the legal

we are filing today with the fda but also europe, hoping to get approval in the next few weeks. in the u.s fda has toormed us they are likely have on december 17 the advisory committee, and i would expect within 24 to 72 hours after that committee, we are working closely in the u.s. with operation warp speed, who is working to make sure that within 24 hours after approval all products would be out the door the vaccination can start so we can help protect as many americans as we can. we are still on track to deliver up to 20 million doses in the u.s. before the end of the year. guy: how do you imagine it actually working? what does it look like when this starts to get rolled out, when people start to come forward and say they want the vaccine were being offered the vaccine? stephane: it will be a typical flu vaccination, just on a scale that has never happened in the world in terms of the number people to be vaccinated at the same time. you take a regular shop, you go to a private room, you show your arm andy clean your inject the product, and then the next one. you need to get your boost 3

u.s. with the fda. here's what he said. >> we are running a very large u.s. specific study as we speak. we've already included 10,000 volunteers in those studies. we'll engage with the fda later in the week to show them that data and depending on the guidance, we'll define the next steps of our strategy here. >> we're going to have to see what the fda decides to do with the data which generated in trials outside the u.s while we wait for the data from the u.s. trial and meanwhile, as moderna and pfizer move through the regulatory process with pfizer already having filed for fda emergency use authorization and moderna expected to file within a week or two. guys >> meg, what would you say is the take away from this as we look back on the other vaccine news that we've had? isn't this like the third vaccine that we've seen that's suggesting 90% plus efficacy i mean that seems like pitching a perfect game >> yeah. it's really good when you see vaccine that's show more than 90% efficacy particularly the pfizer and moderna ones they want to see how robust that 90% figure is. it was in fewer par

what we are going to do, as soon as we got approval by the u.s. fda is to ship the product. ment active in the seasonal flu process. toget the vaccines out hospitals and pharmacies. all the big pharmacy chains in the u.s. have signed up to get thevaccine to provide administration in the pharmacies. this will be available in hospitals, in some rural areas, and gp offices. there's a lot of work going on. this is the government taking care of that. the military is being involved to help with logistics. >> one of the key questions as we all watch the case count climbing around the world is what impact will this have on transmission? what effect will this have on my ability, if i come into contact or debt the virus, to transmit it to others? >> this, we don't know yet. what we know from today's data is you will have a 94% chance to disease.ovid that's obviously a big deal. haidi: that was the amount during the -- the mode turn a -- the moderna ceo. we have heard from tony blair as well as the former u.s. president, bill clinton, in conversation during a panel in the new economy fo

fda for emergency use authorization for its vaccine. the drug giant hopes to produce up to 50 million doses this year with about half going to u.s. moderna will apply soon to fda and expect to deliver 20 million doses to the u.s. by the end of the year. gilead just suffered a blow regarding remdesivir. world health organization is advising doctors against using it to treat covid-19. global health watch dog claims it has no meaningful effect on mortality for patients. remdesivir has been authorized for u.s. emergency use in may. gilead sciences responded saying we are disappointed. w.h.o. guidelines appear to ignore evidence at a time when cases are dramatically increasing and doctors are relying on it as first and only approved antiviral treatment for patients with covid-19. >>> president-elect joe biden spending his 78th birthday meeting with top congressional democrats and working on pandemic plans. meanwhile president trump continues to challenge the election results. he invited top republicans from michigan state's legislature to the white house. it appears to be part of an effort to overturn results in a state he lost by more

doses by the end of this year up to 3 billion total doses coming and they will begin talking to the u.s.'s fda about approvals here in the united states >>> now speaking of the fda, it has also granted emergency use authorization to regeneron for its covid-19 antibody treatment. company submitted its application for the authorization last month after pre-clinical studies showed the therapy reduced the amount of virus and associated damage in the lungs. that stock up 6% right now this is the same antibody treatment that was given to president trump when he contracted covid >>> meantime, nevada's governor issued new restrictions for las vegas's casinos and other steps amid rising case numbers beginning tomorrow, the new rules reduce occupancy limits in casinos, restaurants and bars, from 50% to 25%. it also reduces the cap on public gathering sizes, including entertainment venues to no more than 50 people or 25% capacity, which ever is fewer. we are watching shares to casino stocks they're mixed. when you have positive vaccine news, we know in a few months it looks like we'll have a large swath

either applying for emergency use authorization from the fda. u.s.fficials saying the first vaccinations could begin in a matter of weeks. the chief scientific advisor for operation warp speed. he joins me now. welcome. let's talk first about astrazeneca vaccine issues. first they reported positive results but now there's real questions about whether or not that is true. where do we stand on that? >> we are trying to understand the fullness of the data. the positive side, a second form of technology has demonstrated efficacy. 60% or 90%. it's really important because it validates the virus selected to be part of the vaccine. it's the same as this coronavirus platform. the question is, why would a different schedule giving a lowered dose the first dose and a higher dose for a second dose to immunize? why would that be better giving the same dose twice? frankly, that something we are trying to understand. we're going to measure the immune response it's been in use of two different schedules and see whether there is a better immune response. if there is

fda will meet on december 10th to review pfizer request to okay emergency use. meanwhile trump administration operation warp speed advisor says white house is ready to help district vaccines across the u.s. once regulators grant approval. christina coleman is lye in los angeles with more on that. christina. reporter: hi jon well considering how dangerously fast this deadly virus is spreading the fda is expected to act quick lis in its review of pfizer's vaccine. >> within weeks we could have a decision from fda within 24 hours of that we will have started districting millions of doses of safe and effective vaccine to begin protecting our most vulnerable across america. >> also, execs from competing xoan moderna says it is 95.5 effective and plan to use from fda in coming week as for pfizer its ceo says in addition to seeking approval from the fda the company has initiated rolling applications to other regulatory authorities arntiondz the world. >> we would continue to make sure that we can begin shaping the vaccine immediately after authorization and approval. based on current projections, we expect to produce globally up to 50 million doses in 2020. and to opt 1.3 billion doses by the

either applying for emergency use authorization from the fda. u.s.nations could begin in a matter of weeks. the chief scientific advisor for operation warp speed. he joins me now. welcome.

as infections and hospitalizations surge across the u.s., if the fda gives the green light alex azarses could be shipped out within 24 hours. but president trump is slamming the drug maker accusing the company of sabotaging his reelection bid as the trump campaign tries to o

pfizer and biotech saying they are going to asfor emergency approval by the fda in the u.s.re you concerned that once first vaccination is given and that becomes the story, are you concerned people will drop any attempt at social distancing and wearing face masks? the things we have now to prevent infections? >> i think that is a very legitimate concern. but i also think the opposite will also be true, that we can tell people, hold on, hang on until you get the vaccine because it is for a limited time. have rea challenges about making sure we can produce enough vaccine. that is going to take time. he sure it is equitably distributed within countries and across the world. but ultimately, this does shorten the time horizon. brent: professor of health management and policy at george washington university. we appreciate your time and your insights tonight. thank you and stay healthy. >> thank you. let's take a look at brent: some of the other developments in the pandemic. the united states has reported some of its highest daily coronavirus related death toll since may. the u.s.

we're hoping that in december the u.s. fdaber 8th and 9th they're going to be conve convening their public advisory channel to review the moderna and pfizer vaccine data. hopefully late december, early january, our health care workers who will be first in line may have access to a vaccine. but this is far away from the general public really being able to be vaccinated at their local doctor's office, and we have to stay strong. we have to continue to follow the public health guidelines. >> dr. michelle mcmurray-heath, thank you very much for being on the show this morning. >>> coming up, joe's new book on president truman is out next week, and we've got some great historians and writers lined up to talk about it over the coming days. we'll start with two of our friends, jon meacham and david ignatius straight ahead on "morning joe." what is this? -discover... we call that a window. window. dun-dun-daaa! the first big screen. we really need to limit thunk's window time. not now. the birds are on. in my day we fought them. let me

u.s. is prepared and pfizer is expected to file an application to the fda for emergency use authorizationor its vaccine as soon as today with moderna soon to follow. still, infectious disease expert dr. fauci is telling americans remain cautious. >> i've used that metaphor that the calvary is on the way. if you are fighting a battle and the calvary is on the way, you don't stop shooting, you keep going until the calvary gets here and then you might even want to continue fighting. >> and this morning shares of noiser and moderna are up, moderna up about 3%. >> frank, thank you very much. yesterday we went back toward the big technology and communication names. joining me now is head market strategy of bmi and also income strategist at invesco. thank you very much for joining us daniel, i'll start with you. is there anything that stands out about the current market action over the last couple of days that tells you that maybe there is a direction either way up or down going forward >> thanks for having me. the key thing is differentiation. our expectation is that we continue to see this vie

u.s. consumers. the fda should be allowed to go into every facility in china that is sending their products to the u.s. and we need to make sure that that happens or that those products are unable to come here. finally, we need to disclose where essential drugs and products are coming from and, again, we can do that through federal procurement standards and officials. nowhere are they lenked where the products are coming from and how we can best prepare and protect.inked where the products are coming from and how we can best prepare and protect. >> thank you very much for explaining that to me. let me ask mr. musu and mr. kerska and mr. gilman. your companies have worked to create ppe manufacturing facilities here in the u.s. in response to covid-19 with the goal of creating a homegrown american product, however, not only does china dominate global ppe production. they also dominate ppe component and manufacturing equipment sectors. you have described -- some of those circumstances or at least that fact or t

u.s. surgeon general. former fda commissioner and yale university professor. also on the team, rick bright, the whistle-blower who alleged his early warnings about the pandemic went ignored by the trump administration. >> more people are going to die because scientists are being pushed back. scientists are not being heard. >> reporter: with his transition underway, biden is planning executive orders to undo some of president trump's policies on his first day in office, including rejoining the paris climate agreement and reinstating protections for dreamers. biden's transition still faces one technical hurdle as it waits for a trump appointee at a government agency to sign a letter recognizing his victory and releasing funds for his operation. in the days since his win, biden has seen a wave of messages from world leaders. today speaking by phone with canadian prime minister justin trudeau and congratulatory statements from the king of saudi arabia and israel's prime minister, two men seen as allies of president trump. while the current president has not acknow

now the next steps are we've applied for emergency use authorization by fda in the u.s. eting authorizations globally. and the next step is to have that public dialogue with the fda expert panel. we hope and anticipate the date for that is likely a couple of days away. and once the public has a chance to see the totality of the data and open debate with the expert panel, i'm optimistic that fda will approve this and shortly thereafter with cdc recommendations, we can start to see the deployment of this vaccine to the u.s. population. >> shortly thereafter meaning days, weeks and at what point does sort of your control end and what point does state and federal governments pick up in terms of the, obviously, the distribution and actually the -- getting the vaccines to the hospitals or doctor's offices or wherever they're going to be administered? >> that's a great question. and as you rightly point out, ultimately this is going to be the responsibility of the federal government and the state jurisdictions as far as deployment. once there is marketing authorization, we stand

u.s. the fda urging companies to clearly label foods that have it as an ingredient. dr. people that the fda is able to deal with the pandemic and food allergies simultaneously. this is really a call to awareness issued by the fda. they don't have the legal power to require food manufacturers to label packages if they contain sesame, but they can urge increased awareness and potentially have that happen down the road because sesame allergies apparently on the rise. >> so what are the symptoms of an allergic reaction or if you have a sensitivity to sesame? >> well, you know this affects me personally so it definitely hits home. the typical ones, hives, itchiness around the lips and mouth, redness affecting the eyes even and also gastrointestinal symptoms, of course, if severe, it can lead to anaphylaxis which is life-threatening and requires epinephrine so my medical advice would be get formally tested if you suspect a food allergy. >> but if sesame isn't clearly marked on the label, what foods should we be aware of, and be careful of? >> well, here's the thing, robin. som

u.s. averages more than 100,000 new cases just over the past 5 days. well biden has pledged to make tackling the pandemic his first priority in office, former fda commissioner david kessler and former u.s. surgeon general doctor vivek murthy will lead the team kessler's served as the head of the u c s f medical school from 2003 until 2007. well the biden team also unveiled its official transition website build back better dot com. it lays out the executive actions that he'll take on day one of his presidency. many which are aimed at reversing several of president trump's policies. and you can't talk about president elect joe biden without talking about vice president elect kamala harris. well harris is the first woman and woman of color to hold that office, she's a bay area native she grew up in the east bay shot out to oakland and over the weekend people gathered outside of her childhood home and wrote messages right there on the sidewalk. well during her victory speech saturday night harris said that while she is the first to hold the office she will not be the last this is one mother daughters reaction to the news take a listen. i just think about growin

u.s. population. so the two vaccines that are completing their phase three trial are likely to be filing their files with the fdaor a potential emergency use authorization within the next few weeks. and hopefully, if approved, they could be used for immunization in the u.s. population in the month of december. and we have, we plan to have enough vaccine doses available for use in the u.s. population to immunize about 20 million individuals in the month of december, and another 25 to 30 million per month on an ongoing basis from there on. and as of the month of february or march, if we have more vaccines approved, such as the live vector vaccine, we may be able to immunize a larger number of americans, on an ongoing basis, per month. operation warp speed didn't only focus on vaccines. we also looked at therapeutics. and we have worked with a number of companies developing monoclonal antibodies, in particular, that are able to neutralize the virus. as mr. president said, we have announced partnerships with eli lilly, with regeneron, and with astrazeneca. and, on monday, eli lilly's monoclonal antibody was granted

u.s.. second, we have to do a better protectingng the fda americans in terms of their safety for these products. products that caused a number of deaths in the u.s. coming from china. found a bloodwe pressure medicine was actually tainted with rocket fuel because both the apis and the rocket fuel were being produced at the same facility. that product made its way to u.s. consumers. to --a should be allowed a company in china sending products to the u.s.. we need to make sure that happens, those products are unable to come here. , we need to disclose where essential drugs and products are coming from. we can do that through federal procurement standards so that nowizens and officials k where the products are coming from and how we can best prepare and protect. much foryou very explaining that to me. , your companies have worked to create ppe manufacturing capabilities in the u.s. in response to covid-19 with a goal of creating a homegrown american product. not only does china dominate global ppe production, they dominate ppe component 10 manufacturing equipment sectors. you have described some o

certainly, the fda, once again, in the u.s., we are running a special trial with more than 30,000 participantst's be more patient and see how the fda will react before we make such harsh statements. vonnie: that was the astrazeneca executive vp and head of the biopharmaceuticals business. let's go straight to morgan stanley's head of biotech research, matthew harrison. little bit of controversy. astrazeneca shares went down, the opposite to pfizer and moderna, when their results were announced. it was partially these questions from these analysts about the data. what do you make of the data? i know that your team covers it specifically. of things thatle we can comment. it is encouraging to have another vaccine that is successful. the astrazeneca vaccine can provide utilization in a lot of countries who would potentially receive pfizer or maternal much later. so that is important to keep in mind. out, we, as you pointed are going to need more data. the sample of the smaller initial dose with the full boosting dose is a much smaller sample size compared to those who received both full doses. we

in the u.s., for example, the fda informed us they are likely on december 17, the advisory committee.n, i will expect within 24 to 72 hours. we are working very closely in the u.s. within to make sure that 24 hours after approval, product will be out the door and vaccinations can start so we can help protect as many americans as we can. we are still on track to deliver up to 20 million doses in the u.s. before the end of the year. >> how do you imagine it actually working? what does it look like with this starts to get rolled out? when people start to come forward and say they want the vaccine or being offered the vaccine? stephane: it will be a typical flu vaccination, just that a scale that has never happened in the world in terms of the number of people to be vaccinated at the same time. it is like a regular shot. you go into a private room, you show your arm to the nurse or doc. anti-infective to clean your arm, they inject the product. you need to get your boost 30 days after. a lot of systems developed by the government to track which vaccine in the prime injection. we get the s

10th and moderna is expected to submit to the fda soon now astrazeneca because it has the more mixed data and because these trials come from outside the u.s. they will have to talk to the fda about what is the path forward for them here and what more data might be needed so tbd on that there's also differences among the vaccines in terms of how much they cost are and you can kind of deduce the price per dose of these vaccines based on the supply agreements that they have struck at least here in the united states. astrazeneca is the lowest. they did get support from the u.s. government but you're looking at less than $4 a dose if you take in the development support that they got as well. pfizer, of course, did not take development support from operation warp speed they struck that supply deal so they are getting almost $20 a dose and for moderna, their supply deal is about $15 a doze but if you add in the billion dollars almost that they have received from the u.s. government it's about 25, and for smaller volume agreements they could be striking deals at $37 a dose so quite a span there for all the vaccines finally, we'll just talk about

u.s. in order for the fda to consider this for approval before they get the u.s. >> meg, add this to the list of dumb questions i'm going to ask this morning but when we say 70% efficacy or 62% efficacy or 90% efficacy, that means it works in 90% of the population that has taken in it, it doesn't work in 10% or doesn't work drk not that you have 90% immunity. you have immunity or you don't have immunity, right >> well, there are actually a couple different ways of looking at that. and so the way you get that figure is you have the total number of cases in the trial and then the 90% is the difference between the number in the placebo group and the number in the vaccine group, but there are some vaccines like the flu vaccine that might not prevent you from getting the disease completely but if you do get the disease, it's much milder. and so, vaccines can have all different sort of forms of efficacy and it's not always buy nar, necessarily. >> but the efficacy numbers we don't really know other than it breaks down on the population you're that much less likely to ge

fda clearance? a global trial. they set a mandate that they arm to they add an trial in the u.s., and that they were planning to discussh the fda how they would do that as a way to shore up this higher efficacy number. today is thatid they will probably do a global trial, i imagine because they want to make sure that there is no question as to the ultimate efficacy rate that comes from that lower dosing regime, so we would expect now for them to set up in the near future a second arm not just in the u.s., but globally. that would help with diversity and demographics. guy: let's talk about that. there were some questions surrounding whether or not there was a significant or suitable component of the trial that was in an older age cohort. did he say anything about that and how they will correct that? suzi: again, that would be addressed by the new global trials. the cohort that got the half dose that wasn't originally intended, but they went through with, only went up to age 55. that obviously means we don't know anything about how that lower dosage reacts in older people. this global trial would look to address that, so

the announcement by the fda, late today, represents an important step in the u.s. efforts to expand testing options. the test will require a prescription, likely limiting the initial use. the 30 minute test kit comes from the sierra health, a manufacturer in california. previously the fda had only allowed use of a handful of tests that allow people to collect samples at home, which then had to be shipped to a lab. >>> checking out some of the rainfall totals, it wasn't a lot, depending on where you were. as a an inch of rain and some of the coastal locations, half an inch of rain in the oakland hills and places like that. when you get to livermore and some of the inland spots south, a quarter inch or less. it wasn't a lot of rain for the south bay. drizzling out there, it will be drizzling again tomorrow morning. maybe a little ground fog too, especially in the spots prone to at this time of year. this thing is spinning in. it did a good job and is continuing to do a good job. when you get these storms that come in with a good westerly trajectory, they get pinned up

u.s. adds one point to million more cases in the last week alone but help can be on the way soon as pfizer awaits an emergency approval from the fda the covid-19 vaccine. officials are preparing for an immediate rollout, the white house task force said the u.s. will ship millions of doses of the vaccine within 24 hours as the fda to grant emergency use authorization healthcare workers, and those with serious medical conditions are among the first to receive the vaccine. >> if these vaccines get the ua which i think they will, we will have 20 million people be able to be vaccinated by the middle to the end of december. >> will you take it next month? >> the fda has a granted emergency youth authorization for another covid-19 treatment, the agency gave the green light for regeneron to distribute its monoclonal antibody treatment which mimics the response in fighting off harmful pathogens into the body like viruses, earlier studies on the treatment was effective in containing the virus when getting to people with early stages of infection and reduced medical visits for patients. despite cases surging nationwide, there is a bright spo

they include a former fda commissioner and former u.s. surgeon general. it starts with a coronavirus briefing this morning. >> an announcement to the american people about how he's going to make good on these campaign promises. >> reporter: president-elect biden naming new members of his coronavirus task force making remarks on the virus and the economy, working on a plan to begin january 20th. >> that plan will be built on bedrock science, constructed out of compassion, empathy and concern. >> reporter: meantime the trump campaign is promising a new round of lawsuits today challenging election results. in nevada they claim dead people voted and machines could not verify signatures. >> we pointed out that the voter rolls had a lot of improper voters, and we pointed out the signature verification process were not going to protect the system. >> reporter: president trump tweeting since when does the mainstream media call who our next president will be? certified results could take weeks. >> candidates have the ability to request a recount. we are preparing

u.s. population. arethe two vaccines that completing their phase three trials are likely to be filing aeir files with the fda for potential emergency use operation within the next -- authorization within the next few weeks. hopefully, if approved, they could be used for immunization in the u.s. population in the month of december. and we plan to have enough vaccine doses available for use in the u.s. population to immunize about 20 million individuals in the month of december, and another 25 to 30 million per month on an ongoing basis thereon. from the month of february or march, if we have more vaccines approved, such as the live vector vaccines, we may be able to immunize a large number of americans on an ongoing basis per month. did notn warp speed only focus on vaccines. we also looked at therapeutics and we have worked with a number of companies developing antibodies, in particular that are able to neutralize the virus. we haveresident said, enough partnerships with eli lilly, regeneron and astrazeneca. among the eli lilly's antibody was granted emergency use ientsrization to treat pate that are infecte

as infections and hospitalizations surge across the u.s., if the fda gives the green light alex azar within 24 hours. but president trump is slamming the drug maker accusing the company of sabotaging his reelection bid as the trump campaign tries tove